Nuvectis Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nuvectis Pharma şirketinin toplam hissedar öz sermayesi $11.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $17.3M ve $6.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$17.17m
Eşitlik	US$10.99m
Toplam yükümlülükler	US$6.32m
Toplam varlıklar	US$17.31m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Oct 03

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Jan 31

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

May 04

Recent updates

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Oct 20

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

Jun 26

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

Jan 06

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Oct 03

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Jan 31

Nuvectis Pharma forms scientific advisory board for research and development of drugs

Sep 28

Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04

Aug 05

Nuvectis Pharma declines 13%, announces $15.9M private placement

Jul 27

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

May 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NVCT 'nin kısa vadeli varlıkları ( $17.3M ) kısa vadeli yükümlülüklerini ( $6.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: NVCT un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NVCT borçsuzdur.

Borcun Azaltılması: NVCT son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NVCT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: NVCT serbest nakit akışı her yıl % 25.5 1.2 yıl yetecek nakit akışına sahip olacaktır.

Nuvectis Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Recent updates

Co-Founder recently bought US$98k worth of stock

New minor risk - Market cap size

Nuvectis Pharma, Inc. Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Nuvectis Pharma, Inc.(NasdaqCM:NVCT) dropped from Russell Small Cap Completeness Index

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Nuvectis Pharma, Inc., Annual General Meeting, Jun 13, 2024

Co-Founder recently bought US$51k worth of stock

New major risk - Revenue and earnings growth

Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Nuvectis Pharma, Inc. Announces Initiation of the NXP900 Phase 1a Clinical Trial

New major risk - Revenue and earnings growth

Insider recently bought US$569k worth of stock

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Nuvectis Pharma, Inc. Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

High number of new and inexperienced directors

Nuvectis Pharma, Inc. Announces Fda Grants Fast Track Designation to Nuvectis Pharma's Nxp800 for the Treatment of Platinum-Resistant, Arid1a-Mutated Ovarian Carcinoma

Nuvectis Pharma, Inc Announces Formation of A Scientific Advisory Board

Nuvectis Pharma forms scientific advisory board for research and development of drugs

Nuvectis Pharma Announces Positive Data for NXP800 in A Preclinical Model of ARID1a-Mutated Gastric Carcinoma

Co-Founder recently bought US$169k worth of stock

Co-Founder recently bought US$165k worth of stock

Nuvectis Pharma, Inc. announced that it has received $15.878684 million in funding

Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04

Nuvectis Pharma, Inc. announced that it expects to receive $15.878684 million in funding

Nuvectis Pharma declines 13%, announces $15.9M private placement

Nuvectis Pharma, Inc.(NasdaqCM:NVCT) dropped from Russell Microcap Value Index

Nuvectis Pharma, Inc. Announces Positive Data for NXP900 in A Preclinical Xenograft Model of Group 4 Medulloblastoma

Co-Founder recently bought US$208k worth of stock

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Co-Founder recently bought US$53k worth of stock

Co-Founder recently bought US$153k worth of stock

Nuvectis Pharma, Inc. has completed an IPO in the amount of $16 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin